Antengene Announces Approval of the Phase II Study of Selinexor for the Treatment of Myelofibrosis in China
Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in...
